These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 32224379)

  • 1. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
    Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
    Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
    Rashid ZA; Bardaweel SK
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
    Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
    Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
    Fields GB
    Front Immunol; 2019; 10():1278. PubMed ID: 31214203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
    Das S; Amin SA; Jha T
    Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
    Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
    J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.
    Chen C; Yang X; Fang H; Hou X
    Eur J Med Chem; 2019 Nov; 181():111563. PubMed ID: 31415980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
    Kim IS; Yang WS; Kim CH
    Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present.
    Baidya SK; Amin SA; Jha T
    Eur J Med Chem; 2021 Mar; 213():113044. PubMed ID: 33279289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of 4-phenoxybenzenesulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Mao J; Zhang H; Wang X; Gao J; Tang J; Zhang J
    Biosci Trends; 2020 Jul; 14(3):192-199. PubMed ID: 32389938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
    Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Evaluation of New Oxadiazole, Thiadiazole, and Triazole Derivatives as Potential Anticancer Agents Targeting MMP-9.
    Özdemir A; Sever B; Altıntop MD; Temel HE; Atlı Ö; Baysal M; Demirci F
    Molecules; 2017 Jul; 22(7):. PubMed ID: 28677624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of research on matrix metalloproteinases (MMPs) in India.
    Bulbule A; Saraswati S; Kundu GC
    Expert Opin Ther Targets; 2011 Jun; 15(6):671-5. PubMed ID: 21476880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fragment-based structural analysis of MMP-2 inhibitors in search of meaningful structural fragments.
    Banerjee S; Amin SA; Jha T
    Comput Biol Med; 2022 May; 144():105360. PubMed ID: 35278773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).
    Almutairi S; Kalloush HM; Manoon NA; Bardaweel SK
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.